Background {#Sec1}
==========

Chronic Obstructive Pulmonary Disease (COPD) is characterized by an abnormal inflammatory response to noxious environmental stimuli in the lung \[[@CR1]\]. Persistent lung inflammation leads to the development of emphysema and airway disease, of which goblet cell hyperplasia (GCH) is a crucial component \[[@CR2]\]. GCH is a common phenomenon in COPD, regardless of the presence or absence of chronic bronchitis (CB) \[[@CR3]--[@CR5]\]. It has been shown that subjects with more airflow obstruction have a greater burden of mucus in the small airways \[[@CR4]\]. In addition, a bronchoscopic study in smokers with and without airflow obstruction demonstrated more GCH in the large airways, particularly in those with COPD \[[@CR5]\]. However, there is a large disconnect between symptoms of cough and sputum and mucus burden \[[@CR6]\]. The most well characterized pathologic index described by Reid has shown only a weak relationship between chronic bronchitic symptoms \[[@CR7]\].

While well described in asthma, the inflammatory mechanisms responsible for GCH in COPD are not well known. It has been established that subjects with airflow obstruction demonstrate greater neutrophilic, lymphocytic, and macrophage infiltration in the lung parenchyma which increases as lung function declines \[[@CR3], [@CR4], [@CR8]\], but how trafficking of these cells to the airways occurs is not known. To complicate matters, it has been increasingly recognized that COPD is associated with significant systemic inflammation, but the association between systemic inflammation and lung GCH is not known. We sought to characterize the systemic cytokine profiles and relate them to GCH. We hypothesized that elevations in systemic cytokines would be associated with increased GCH as a result of immune trafficking to the lung and subsequent mucin production. Specifically, because neutrophils and macrophages are associated with mucin gene expression \[[@CR9]\], we hypothesized that plasma proinflammatory chemokines which mobilize neutrophils and macrophages, particularly interleukin-8 (CXCL8), monocyte chemotactic proteins-1 and −3 (CCL2 and CCL7), macrophage derived chemokine (CCL22), and macrophage inflammatory proteins-1α and -1β (CCL3 and CCL4), would correlate with GCH in smokers and ex-smokers with and without COPD.

Methods {#Sec2}
=======

This study was approved by the Temple University School of Medicine IRB (protocol no. 20687). Written informed consent to participate was obtained by the PI (VK). We performed phlebotomy and bronchoscopy on 25 subjects (six nonsmokers, 11 healthy smokers, and eight COPD subjects). Inclusion and exclusion criteria are summarized in Table [1](#Tab1){ref-type="table"}. Briefly, for COPD subjects, we included those with an FEV~1~ between 30 and 60 %, because this group is considered at high risk for exacerbation. Healthy smokers needed to have at least a 10-pack year history of smoking. Healthy nonsmokers served as a control group. We excluded those with upper airway disease such as allergic rhinitis or chronic sinusitis, those with a COPD exacerbation, upper respiratory tract infection, or acute sinusitis within 6 weeks prior to bronchoscopy in order to exclude the possible effects of upper airway GCH on lower airway GCH. We also excluded those with abnormal coagulation profile or on anticoagulation within 6 half-lives of the bronchoscopy, and those with a known allergy to lidocaine. Subjects treated with inhaled corticosteroids had a washout period of 4 weeks prior to bronchoscopy, to negate their possible effects on GCH. We excluded those deemed high risk for discontinuation of inhaled corticosteroids (e.g., history of frequent exacerbations).Table 1Inclusion and exclusion criteriaInclusion criteria Age between 40 and 70 years Diagnosis of COPD or at risk for COPD Smoking History \>10 pack years (for nonsmokers less than 100 cigarettes in lifetime) FEV~1~ 30--60 % (COPD group), normal FEV~1~ (Healthy Smoker Group) English speakingExclusion criteria Diagnosis of chronic sinusitis or allergic rhinitis Presence of other lung disease (including asthma) Pregnancy Sinusitis or URI within the last 6 weeks COPD Exacerbation within 6 weeks of screening visit Presence of infiltrate or mass on CT scan Anticoagulation or antiplatelet therapy within 6 half lives of bronchoscopy Known allergy to lidocaine Predisposition to bleeding Chronic treatment with steroids, oral or inhaled that cannot be discontinued for 4 weeks prior to study Unwillingness to participate in study

Six endobronchial biopsies per subject were performed. After premedication with intravenous fentanyl and midazolam, bronchoscopy was performed using local anesthesia with topical lidocaine. Endobronchial mucosal biopsies were performed at carinae of segmental airways, in the right lower lobe, right middle lobe, and right secondary carina (branch point between right upper lobe and bronchus intermedius). Plasma was collected on the same day as bronchoscopy. Briefly, 20 ml of blood was collected by venous puncture into vacutainers containing EDTA as the anticoagulant. The blood was layered on 15 ml of Ficoll-Paque Plus (GE Healthcare), and centrifuged for 40 min at 300 g. The plasma layer was recovered and stored at −80 °C.

GCH was measured by measuring mucin volume density (MVD) using stereological techniques on periodic acid fast-Schiff stained samples. Examples of images from a healthy nonsmoker and a healthy smoker are shown in Fig. [1](#Fig1){ref-type="fig"}. Mucin volume was measured using a modified model described by us \[[@CR10]\] using Image J. Length of basement membrane (L~BM~) and total area of mucin granules (MA) were measured. MVD (μL/mm^2^) was calculated using stereologic techniques as described previously \[[@CR11], [@CR12]\]: MVD = MA/(L~BM~)(4/π).Fig. 1Examples of mucosal biopsies from (**a**) and (**b**) healthy nonsmokers, (**c**) and (**d**) healthy smokers,and (**e**) and (**f**) COPD subjects, taken at 40×. Specimens stained with periodic acid Schiff-Alcian Blue, staining goblet cells blue/purple

Plasma was analyzed for cytokine and chemokine levels using the Luminex platform. EMD Millipore cytokine kit, HCYTOMAG-60K-29, was purchased and the following analytes measured: IL-1β, IL-4, IL-6, CXCL8, IL-9, IL-12p40, IL-15, IL-17, CCL2, CCL7, CCL22, CCL3, CCL4, Eotaxin, IP-10, interferon-gamma (IFN-γ), granulocyte colony stimulating factor (G-CSF), epidermal growth factor (EGF), IFN-α2, transforming growth factor-alpha (TGF-α), and vascular endothelial growth factor (VEGF).

Statistics {#Sec3}
==========

Statistical analysis was performed using SPSS v22 (SAS, Cary, NC) and graphs created with Graphpad Prism v6.03. Differences between the three groups (nonsmokers, healthy smokers, COPD) were assessed using one-way ANOVA or Chi squared test. Post hoc tests after ANOVA were performed using Bonferroni correction. In addition, an analysis of all current smokers vs. all non- or ex-smokers was performed with *t* test and Chi squared test. A *p* value of \<0.05 was considered statistically significant. Correlations between plasma cytokines and MVD were performed using Spearman's correlation.

Results {#Sec4}
=======

The clinical and physiologic characteristics, as well as the MVD, of the subjects are summarized in Table [2](#Tab2){ref-type="table"}. There was no statistically significant difference in age, gender, or body mass index between groups. There were more African-Americans in the COPD group compared to the healthy smoker and nonsmoker groups. By definition, the COPD group had worse spirometry compared to the healthy smoker and nonsmoker group, and smoking history was not different between the COPD and healthy smoker groups. Five out of eight (62.5 %) of the COPD group were current smokers, compared to 100 % in the healthy smoker group. Five out of eight (62.5 %) in the COPD group had chronic bronchitis, defined by chronic cough and sputum at least 3 months a year for at least two consecutive years. Two out of the 11 healthy smokers (18.2 %) had chronic bronchitis. To our surprise, the MVD was greatest in the healthy smoker group (27.78 ± 10.24 μL/mm^2^) compared to the nonsmoker group (3.42 ± 3.07 μL/mm^2^, *p* \<0.001). In the COPD group, the MVD was less than the healthy smoker group (16.82 ± 16.29 μL/mm^2^), but the difference was not statistically significant (*p* = 0.216).Table 2Demographic factors, BAL results, mucin volume densityNonsmokersHealthy smokersCOPD*n* = 6*n* = 11*n* = 8*p*Age (years)47.60 ± 11.8249.58 ± 5.5757.0 ± 4.660.052Gender (male, n (%))4 (66.7)4 (36.3)5 (62.5)0.327BMI (kg/m^2^)31.13 ± 5.2630.78 ± 4.7429.30 ± 5.880.743Race^a^ (White, n (%))3 (50.0)2 (18.2)0 (0)0.035FEV~1~ ( % pred)89.50 ± 20.52\*101.17 ± 16.30\*46.25 ± 8.83\<0.0001FVC ( % pred)92.90 ± 16.23103.67 ± 16.87\*74.13 ± 12.700.001FEV~1~/FVC88.2 ± 21.70\*96.67 ± 6.14\*52.38 ± 11.95\<0.0001Smoking History (pack years)0\* \*\*25.58 ± 10.6622.25 ± 9.00\<0.0001Current Smoking (n, %)0 (0)11 (100)5 (62.5)\<0.0001Chronic Bronchitis (n, %)0 (0)2 (18.2)5 (62.5)0.006MVD (μL/mm^2^)3.42 ± 3.07\*\*27.78 ± 10.2416.82 ± 16.290.002^a^Other race is Black. \**p* \<0.05 compared to COPD, \*\**p* \<0.05 compared to Healthy Smokers

The levels of plasma chemokines and cytokines are summarized in Table [3](#Tab3){ref-type="table"}. Plasma CXCL8 was greatest in the healthy smoker group (11.05 ± 8.92 pg/mL) compared to the nonsmoker group (1.20 ± 21.92 pg/mL, *p* = 0.047) and COPD group (6.01 ± 5.90 pg/mL, *p* = 0.366). See Fig. [2](#Fig2){ref-type="fig"}. Similar trends were seen in CCL22 and CCL4, where concentrations of these chemokines were greatest in the healthy smoker group, and significantly different from the nonsmoker group but not the COPD group. CCL7 was greatest in the COPD group (50.74 ± 25.88 pg/mL) compared to the nonsmoker group (17.33 ± 14.44 pg/mL, *p* = 0.028) and the healthy smoker group (40.66 ± 22.34 pg/mL, *p* = 0.167). There were no significant differences between groups in CCL2, CCL3, or other cytokines.Table 3Plasma chemokinesNonsmokers (*n* = 6)Healthy smokers (*n* = 11)COPD (*n* = 8)*P*ChemokinesEotaxin83.92 ± 57.4196.16 ± 58.8696.42 ± 75.400.920CXCL81.20 ± 21.92\*11.05 ± 8.926.01 ± 5.900.028IP10233.94 ± 125.07671.55 ± 544.81670.36 ± 751.530.287CCL2200.98 ± 128.03310.63 ± 149.19207.02 ± 76.060.106CCL717.33 ± 17.44\*\*40.66 ± 22.3450.74 ± 25.880.031CCL22714.23 ± 524.71\*1335.51 ± 486.74\*\*750.37 ± 251.390.009CCL317.44 ± 25.477.88 ± 21.728.33 ± 3.550.255CCL49.69 ± 10.50\*42.04 ± 24.4825.98 ± 15.600.009Th1IFNγ4.21 ± 2.639.58 ± 6.1319.24 ± 28.760.253IL12p40Undetectable38.97 ± 8.01\*\*20.44 ± 17.220.035Th2IL410.71 ± 13.2015.35 ± 12.2647.77 ± 81.070.256IL91.16 ± 1.831.71 ± 1.442.66 ± 2.950.389Th17GCSF83.92 ± 57.4174.14 ± 81.8025.79 ± 25.960.059IL611.39 ± 2.589.46 ± 2.4664.27 ± 163.010.410IL17Undetectable8.76 ± 0.878.62 ± 1.030.809OtherEGF12.65 ± 3.3113.96 ± 8.1919.16 ± 19.660.559IFNα217.19 ± 11.2857.43 ± 37.4267.87 ± 71.160.155IL1β2.86 ± 4.441.97 ± 2.595.30 ± 7.010.323IL109.35 ± 7.736.78 ± 6.0816.11 ± 27.390.478IL155.18 ± 3.525.53 ± 3.205.75 ± 5.190.965TGFαUndetectableUndetectableUndetectableVEGF130.03 ± 100.23195.44 ± 55.90258.95 ± 295.520.427\**p* \<0.05 vs. healthy smokers, \*\**p* \<0.05 vs. COPDFig. 2Plasma cytokines **a**) CXCL8, **b**) CCL4, **c**) CCL22 and **d**) MVD by group. \**p* \<0.05 compared to healthy smokers

Subjects were subsequently divided into current smokers (including healthy smokers and COPD subjects) and non- or ex-smokers (nonsmoker group plus COPD subjects that quit smoking). As there were only three former smokers in the analysis, they were grouped together with the non-smokers. Plasma cytokine levels were compared between these two groups. The results are summarized in Table [4](#Tab4){ref-type="table"}. The concentration of plasma CXCL8 was greater in the current smoker group compared to the non- or ex-smokers. Plasma CCL22 and CCL4 were also greater in the current smoker group. There were no significant differences in CCL2, CCL3, CCL7, or other cytokines between these groups. MVD was greater in the current smokers compared to the nonsmokers. See Fig. [3](#Fig3){ref-type="fig"}. Finally, there was a moderate correlation between plasma CXCL8 and MVD (*r* = 0.552, *p* = 0.003). See Fig. [4](#Fig4){ref-type="fig"}. There were no significant correlations with other plasma chemokines.Table 4Plasma chemokines and mucus volume density in current smokers vs. non- or ex-smokersNon- or ex-smokers (*n* = 9)Current smokers (*n* = 16)*p*ChemokinesEotaxin88.87±84.9095.87±51.470.791CXCL82.11±3.989.43±7.94**0.016**IP10295.19±157.43713.20±676.250.082CCL2213.03±113.31265.32±135.190.329CCL736.33±34.8240.65±20.230.686CCL22653.56±439.541239.50±498.06**0.006**CCL314.95±20.707.78±1.830.149CCL414.99±16.2035.86±21.99**0.019**Th1IFNγ18.17±31.318.86±5.150.222IL12p4030.15^a^34.76±15.350.778Th2IL446.94±86.5916.02±13.720.144IL92.43±3.421.70±1.300.426Th17GCSF12.95±25.7156.46±68.360.079IL671.61±171.169.48±3.390.129IL179.30^a^8.64±0.930.510OtherEGF18.43±19.3514.18±8.770.434IFNα246.90±77.8455.08±35.520.708IL1β5.47±7.022.37±3.570.137IL1019.90±28.456.47±5.150.059IL156.89±5.074.86±3.230.217TGFαUndetectableUndetectableVEGF156.87±93.82228.21±221.000.366MVD7.41±7.5624.07±13.70**\<0.0001**Plasma chemokines expressed as pg/mL. MVD expressed as μL/mm^2a^Only one sample with detectable levelsFig. 3Plasma Cytokines **a**) CXCL8, **b**) CCL4, **c**) CCL22, and **d**) MVD by current smoking. *NS* Non- or ex-smokers, *CS* Current smokers. \**p* \<0.05 compared to current smokersFig. 4Relationship between mucus volume density and plasma CXCL8 concentrations

Discussion {#Sec5}
==========

As previously shown, we found that GCH was greatest in smokers without airflow obstruction compared to COPD subjects and nonsmokers, and that this effect was primarily driven by current smoking \[[@CR13]\]. In this small cohort, we demonstrated that plasma chemokines CXCL8, CCL22, and CCL4 were also greatest in the healthy smoker group, following the same pattern as the degree of GCH. These cytokines were also greater in those currently smoking, suggesting a causal relationship between smoking and these cytokines which result in GCH. Interestingly, we found that CCL7 was greatest in the COPD group, but found no other significant differences in other cytokines between groups. Finally, we showed that there was a moderate correlation with plasma CXCL8 concentrations with MVD. These findings suggest that smoking upregulates these plasma neutrophil and macrophage chemokines which result in the development of lung GCH.

Several cytokines and biomarkers have been examined in COPD subjects in various compartments, including plasma, sputum, and BAL. The most well characterized ones include C-reactive protein, fibrinogen, surfactant protein-D, IL-6, TNF-α, and CXCL8 \[[@CR14]--[@CR17]\]. However, prior literature has emphasized levels in COPD subjects in the chronic stable state compared to controls, compared to periods of exacerbation, or in response to therapy \[[@CR14], [@CR15], [@CR17]--[@CR19]\]. Hurst et al. found that systemic levels of IL-6 correlated with sputum concentrations of CXCL8 during exacerbations compared to the chronic stable state \[[@CR15]\]. Sin et al. reported that inhaled fluticasone and fluticasone/salmeterol combination reduced systemic levels of surfactant protein-D but not C-reactive protein or IL-6 \[[@CR19]\]. Few studies have addressed the role of cytokines in relationship to GCH in smokers with and without airflow obstruction. Interestingly, we found that the levels of certain chemokines, particularly CXCL8, were significantly correlated with GCH. Another interesting finding was that smokers without airflow obstruction had greater MVD compared to COPD subjects, a novel finding compared to prior studies \[[@CR4], [@CR5]\].

CXCL8 has been the subject of many prior investigations in COPD. CXCL8 is a potent neutrophil chemoattractant \[[@CR20]\], which is a known stimulant of mucin production and degranulation of mucin stores \[[@CR21]\]. CXCL8 also regulates mucin gene expression at the posttranscriptional level \[[@CR22]\]. A bronchoscopic study of 39 COPD subjects and 18 healthy controls found that CXCL8 in BAL was significantly higher in frequent exacerbators \[[@CR23]\]. Furthermore, recent studies have shown that CXCL8 levels are significantly elevated in the blood in COPD patients, and that CXCL8 (as well as CCL4) levels correlate with mortality, exacerbation rate, and BODE scores, and inversely correlate with FEV~1~ and DLCO \[[@CR24]--[@CR26]\]. Moreover, analysis of the levels of CXCL8 in BAL and sputum found higher levels of sputum CXCL8 in COPD subjects compared to healthy smokers and nonsmoking controls but no difference in BAL CXCL8 \[[@CR27]\]. However, one study found BAL CXCL8 levels to be greater in smokers and COPD subjects compared to normal controls \[[@CR28]\], and another study showed that BAL CXCL8 levels could distinguish current smokers with emphysema from those without emphysema \[[@CR29]\]. In contradistinction to prior studies, we found that plasma CXCL8 levels to be highest in the healthy smoker group and was highly dependent on current smoking. Moreover, We found a moderate correlation between plasma CXCL8 and MVD, a novel finding in comparison with current literature, and as the greatest levels of each were found in current smokers, this association suggests a relationship with plasma neutrophils and the development of GCH in the lung. It is known that cigarette smoke causes influx of neutrophils and macrophages to the lung. Cigarette smoke extract has been shown to increase CXCL8 release from bronchial epithelial cells in a concentration- and time-dependent manner \[[@CR30]\]. Cigarette smoking acutely increases plasma neutrophil activation as well in young smokers susceptible to the development of COPD (defined as those with familial aggregation) \[[@CR31]\]. Our findings support this phenomenon by demonstrating the upregulation of the plasma levels of the chemokines CXCL8, CCL4, and CCL22 in current smokers.

Some studies have tried to relate cytokines with the presence of chronic bronchitis. A bronchoscopic study of 42 subjects with chronic bronchitis (with and without airflow obstruction) and 13 healthy controls found increased activity of CXCL8, myeloperoxidase, hyaluronan, and eosinophil cationic protein \[[@CR32]\]. Sputum CCL2 levels have recently been shown to be increased in COPD subjects with chronic bronchitis compared to COPD subjects without chronic bronchitis \[[@CR33]\]. In this study, sputum neutrophil and eosinophil counts were also higher in the chronic bronchitic group. Moreover, Monzon et al. described a CCL2/CCR2B dependent loop which appeared to upregulate mucin gene expression in human airway epithelial cells \[[@CR34]\]. In contrast, de Moraes et al. found an association with serum IL-6 levels in ex-smoker COPD subjects with chronic bronchitis, but were unable to demonstrate a relationship of IL-6 or CXCL8 with disease severity \[[@CR35]\].

There is growing evidence that CCL22 may be involved in the pathogenesis of chronic lung inflammation. CCL22 is produced predominantly by monocytes, macrophages, and dendritic cells, and is a potent chemoattractant for macrophages, NK cells, and some T cells \[[@CR36]\]. It is apparent that the levels of CCL22 mRNA and protein are elevated in both lung tissue and lavage fluid in COPD \[[@CR37]\]. The levels of CCL22 are also elevated in the lavage fluid obtained from patients with idiopathic pulmonary fibrosis \[[@CR38]\]. Furthermore, Frankenberger et al. recently reported a 10-fold increase in the expression of CCL22 by macrophages obtained from BAL of either COPD patients or smokers \[[@CR39]\]. Finally, Belperio et al. have shown that the levels of CCL22 are overexpressed in a bleomycin model of murine pulmonary fibrosis \[[@CR40]\]. Similarly, the levels of this chemokine are significantly increased in the lungs in studies of a rat model of radiation pneumonitis-related pulmonary fibrosis \[[@CR41]\].

Recent reports using experimental animal models have suggested that CCL4 may play an important role in the induction of lung inflammation following exposure to tobacco smoke. Ma et al. report in increase in production of CCL4 in the lungs of mice subjected to daily administration of cigarette smoke \[[@CR42]\]. The receptor for this chemokine is CCR5, and the administration of tobacco smoke to CCR5-deficient mice shows substantially attenuated lung inflammation when compared to mice which express normal levels of CCR5 \[[@CR42], [@CR43]\]. These results suggest that the CCL4-CCR5 response loop may make a substantial contribution to the development of lung inflammation associated with smoke exposure. However, it should be pointed out that Meuronen et al. have reported that CCL4 levels are significantly decreased in the BAL of asymptomatic long-term smokers \[[@CR44]\]. This report is in contrast to the results reported herein, or with the results of studies with chronic bronchitis patients in which the levels of CCL4 were found to be increased in lavage fluid \[[@CR45]\]. An explanation for the disagreement in the results from these studies is not clear at this time. Less is known about CCL7 in COPD, but it has been described in other inflammatory diseases including asthma, multiple sclerosis, and rheumatoid arthritis \[[@CR46]\]. We found that CCL7 plasma levels were greatest in the COPD group. Further study in a larger cohort is needed to validate these findings.

In the present study, some cytokines, and GCH, are downregulated in COPD patients compared to healthy smokers. Other studies have found that proinflammatory cytokines and GCH are upregulated in COPD \[[@CR4], [@CR5], [@CR14]\]. Corticosteroids were withheld for four weeks prior to phlebotomy and bronchoscopy, so it is doubtful that the prior use of inhaled corticosteroids is responsible. We suggest that current smoking has a more powerful influence on circulating cytokine levels in this cohort.

This study has several limitations. Firstly, the sample size is small, meaning studies of greater magnitude are needed in order to confirm these findings. The biopsies are of the large airways, which may not represent disease of the smaller airways where airflow obstruction is thought to occur. Sampling error of the mucosa is a potential issue, but the biopsies were performed in systematic fashion and therefore less likely to be the cause of the findings. There were significant differences in racial distribution between the 3 groups, which may have had bearing on the results. By design, the study recruited those with moderate to severe COPD, so little can be said about those with milder disease. Finally, our data suggest that plasma levels of four chemokines statistically correlate with COPD, and three of these (CXCL8, CCL4 and CCL22) also correlate with mucous volume density. Nevertheless, at this point little can be said about immune trafficking of inflammatory cells into the lung, as plasma cytokine levels and GCH were measured separately and are purely associations at this point. Additional studies will be necessary to more fully assess the contribution of chemokine-driven inflammatory cell recruitment to the degree of lung disease, particularly mucous production, in COPD.

Conclusions {#Sec6}
===========

We found greater degrees of GCH in the healthy smoking group and all current smokers, which correlated with differences in plasma CXCL8, CCL22, and CCL4 between groups in similar fashions. These associations suggest that smoking has a systemic effect on circulating cytokine levels that lead to the development of GCH. Further study is needed to corroborate these findings in a larger cohort.

ANOVA

:   Analysis of variance

BAL

:   Bronchoalveolar lavage

CB

:   Chronic bronchitis

COPD

:   Chronic obstructive pulmonary disease

CCL2

:   Monocyte chemotactic protein-1

CCL3

:   Macrophage inflammatory proteins-1α

CCL4

:   Macrophage inflammatory proteins-1β

CCL7

:   Monocyte chemotactic protein-3

CCL22

:   Macrophage derived chemokine

CXCL8

:   Interleukin 8

DLCO

:   Diffusing capacity of carbon monoxide

EGF

:   Epidermal growth factor

FEV~1~

:   Forced expiratory volume in 1 s

G-CSF

:   Granulocyte colony stimulating factor

GCH

:   Goblet cell hyperplasia

IFN-α2

:   Interferon-alpha2

IFN-γ

:   Interferon-gamma

L~BM~

:   Length of basement membrane

MA

:   Total area of mucin granules

MVD

:   Mucin volume density

TGF-α

:   Transforming growth factor-alpha

VEGF

:   Vascular endothelial growth factor

**Competing interests**

VK has participated in clinical trials sponsored by Boehringer Ingelheim, GlaxoSmithKline, MedImmune, and Roche pharmaceuticals and has served on an advisory committee for CSA (Sum total \$1000). VK's work was supported by NHLBI K23HL094696. MO, TJR, WDC, and HD have nothing to disclose. The work from TJR and WDC were supported by NIH P30DA13429. GJC has served on Advisory Committees for Boehringer Ingelheim, CSA, Amirall and Holaira. All of these sums are less than \$2,500. GJC has received research grants from: Boehringer Ingelheim, AstraZeneca, MedImmune, Pearl, Actelion, GlaxoSmithKline, Forest, Aeris, Therapeutics, Pulmonx and PneumRx. All research grant monies are deposited and controlled by Temple University.

**Authors' contributions**

VK, WDC, TJR, and GJC contributed to study design, performance of experiments, writing of the manuscript, and data analysis. HD and MO took images for the measurement of mucin volume density and contributed to data analysis. VK is the guarantor for the overall content. All authors read and approved the final version of the manuscript.

**Authors' information**

Not applicable.

**Availability of data and materials**

Not applicable.

VK issupported by NHLBI K23HL094696. TJR and WDC are supported by NIH P30DA13429.
